Piper Sandler analyst David Westenberg upgraded Adaptive Biotechnologies to Overweight from Neutral with a price target of $14, up from $7.50. If the company can grow minimal residual disease revenue at 50% as is expected in 2023, the stock would deserve a 10-times revenue multiple on its MRD business, Westenberg tells investors in a research note. In addition, the analyst thinks estimates and the stock have upside from near term immune medicine partnership milestone and other collaboration revenue. The long term "dream-the-dream" of an annual immune system scan "represents a free call option," writes Westenberg. He likes Adaptive’s valuation following a "rough" 2022 and the potential near term uptake of minimal residual disease.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ADPT:
- Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
- Adaptive Biotechnologies to present more than 30 abstracts at ASH meeting
- Adaptive Biotechnologies Announces Launch of clonoSEQ® to Assess Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using Circulating Tumor DNA (ctDNA)
- Adaptive Biotechnologies announces launch of clonoSEQ
- Adaptive Biotechnologies to Participate in the Piper Sandler Healthcare Conference
